Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort to Evaluate the Ability of Different Body fLuid-derived Approaches to Detect EArly-stage Cancers Among High-risk Individuals

NCT06907095 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT06907095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort to Evaluate the Ability of Different Body fLuid-derived Approaches to Detect EArly-stage Cancers Among High-risk Individuals
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Not applicable
Overall status
Recruiting
Start date
March 16, 2026
Completion date
June 30, 2030
Enrollment
5,909 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

risk of breast cancer, risk of colorectal cancer, risk of endocrine cancers, risk of gynaecological cancer, risk of head and neck cancers, risk of hematologic malignancies, risk of hepatic cancers, risk of kidney cancer, risk of lung cancer, risk of mesothelioma, risk of neoplasia, risk of prostate cancer, risk of second malignancy in individuals treated for a childhood cancer, risk of several cancer types, risk of skin cancers except basal-cell carcinomas, risk of upper gastrointestinal cancers, risk of urothelial cancers